Dr Françoise KREUTZ

Spécialisations

• Medecine générale (Université de Liège, 1985)

Centres d'intérêt

• Recherches cliniques de phase I, II et III (data management)

Mandats

• Coordinatrice médicale des études cliniques pour le service d'Oncologie du CHC
• Vice-présidente et secrétaire du Comité d´éthique médicale du CHC

Publications

• Demolin G, Focan C, Plomteux O, Kreutz F, Moeneclaey N, Focan-Henrard D. Chemotherapy for human gastric cancer: a review. Rev Med Liege. 2008 Sep; 63(9): 532-41. 
• Lévi F, Focan C, Karaboué A, de la Valette V, Focan-Henrard D, Baron B, Kreutz F, Giacchetti S.  Implications of circadian clocks for the rhythmic delivery of cancer therapeutics. Adv Drug Deliv Rev. 2007 Aug 31; 59(9-10): 1015-35.
• Focan C, Kreutz F, Longrée L, Graas MP, Moeneclaey N, Demolin G, Focan-Henrard D. Interest of chronotherapy in multidisciplinary management of oesophageal and gastric cancers. Pathol Biol (Paris). 2007 Apr-May; 55(3-4): 181-5. 
• Focan C, Bury J, Matus G, Graas MP, Kreutz F, Longree L, Moeneclaey N, David A, Focan-Henrard D. Adjuvant chemotherapy for Dukes B2 and C colon cancer combining 5-fluorouracil and folinic acid with or without carboplatin. Feasibility and comparison between standard and chronomodulated deliveries. Pathol Biol (Paris). 2005 Jun; 53(5): 281-4. 
• Focan C, Kreutz F, Graas MP, Longrée L, Moeneclaey N, David A, Focan-Henrard D. Feasibility survey (Phase I-II) of a four drugs combination (5-fluorouracil, folinic acid, carboplatin and irinotecan) delivered using a chronomodulated infusion in the treatment of advanced colorectal cancer. Pathol Biol (Paris). 2005 Jun; 53(5): 277-80. 
• Focan C, Kreutz F, Longrée L, Graas MP, Focan-Henrard D, Moeneclaey N, David A, Biquet JF, Materne R, Weerts J, Delforge M. Chronotherapy combining 5-fluorouracil, folinic acid and carboplatin as first line treatment in metastatic colorectal cancer. A phase 2 study. Pathol Biol (Paris). 2005 Jun; 53(5): 273-6. 
• Focan C, Kreutz F, Moeneclaye N, Focan-Henrard D. Randomised study to evaluate the chronotolerance of a combination infusional chemotherapy with 5-fluorouracil, folinic acid and carboplatin in non small cell lung cancer (NSCLC) patients. Pathol Biol (Paris). 2003 Jun; 51(4): 204-5. 
• Focan C, Focan-Henrard D, Kreutz F, Moeneclaey N. Chronobiological considerations for the management of human head and neck cancer. Pathol Biol (Paris). 2003 Jun; 51(4): 201-3. 
• Focan C, Kreutz F, Focan-Henrard D, Moeneclaey N, Gillard V, Delforge M, Dallemagne B, Weerts J, Closon MT, Honoré P. Chronopharmacologic approach to the administration of anticancer agents in pancreatic adenocarcinoma. Pilot experience. Rev Med Liege. 2000 Mar; 55(3): 149-53.
• Focan C, Kreutz F, Focan-Henrard D, Moeneclaey N.Chronotherapy with 5-fluorouracil, folinic acid and carboplatin for metastatic colorectal cancer; an interesting therapeutic index in a phase II trial. Eur J Cancer. 2000 Feb; 36(3): 341-7. 

Communications scientifiques (communications orales, posters)

• Roland S, Kreutz F, Focan-Henrard D, Moeneclaey N, Dallemagne B, Weerts J, Delforge M, Focan C. Chrontherapy with 5-Fluorouracil, Folinic Acid and Carboplatin for stomach cancer. A pilot study. Award for a selected oral presentation at the Second BSMO annual symposium. January 21-22, 2000. Brussels, Belgium. 
• Focan C, Kreutz F, Focan-Henrard D, Moeneclaey N. Interest of Low-dose carboplatin in densified chronotherapy with fluorouracil and folinic acid for metastatic colorectal cancer. A phase II trial. BSMO Annual Symposium. January 16, 1998. Brussels, Belgium.  

Cours

• EORTC June 2008 : Clinical Trial Statistics for non statisticians.